Crystal Arthropathies

  • Eleftherios Pelechas
  • Evripidis Kaltsonoudis
  • Paraskevi V. Voulgari
  • Alexandros A. Drosos


Crystal arthropathies are a group of joint disorders due to deposition of crystals in and around joints which lead to joint destruction and soft tissue disturbances (swelling, redness, masses etc.). Clinical presentations of the different types of crystal arthropathies are often characteristic enough to differentiate them from each other, but mistakes can be made, leading to delayed or incorrect management. Gout is the most common form of crystal arthropathies. First identified by the Egyptians in 2640 BC and later by Hippocrates in the 5th century BC, who referred to as “the unwalkable disease”. Throughout history, gout has been associated with rich foods and excessive alcohol consumption and has been referred to as the “disease of kings”. Calcium pyrophosphate dihydrate disease (CPPD/pseudogout) and basic calcium phosphate (BCP/hydroxyapatite) are the two other forms of crystal arthropathies.

References and Further Reading

  1. Abhishek A, Doherty M. Epidemiology of calcium pyrophosphate crystal arthritis and basic calcium phosphate crystal arthropathy. Rheum Dis Clin N Am. 2014;40(2):177–91.CrossRefGoogle Scholar
  2. Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet. 2010;377:165.CrossRefGoogle Scholar
  3. Cho NS, Lee BG, Rhee YG. Radiologic course of the calcific deposits in calcific tendinitis of the shoulder: does the initial radiologic aspect affect the final results? J Shoulder Elb Surg. 2010;19(2):267–72.CrossRefGoogle Scholar
  4. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039–52.CrossRefGoogle Scholar
  5. De Vera MA, Marcotte G, Rai S, et al. Medication adherence in gout: a systematic review. Arthritis Care Res. 2014;66:1551.CrossRefGoogle Scholar
  6. Filippou G, Filippucci E, Tardella M, et al. Extent and distribution of CPP deposits in patients affected by calcium pyrophosphate dihydrate deposition disease: an ultrasonographic study. Ann Rheum Dis. 2013;72(11):1836–9.CrossRefGoogle Scholar
  7. Gutierrez M, Di Geso L, Salaffi F, et al. Ultrasound detection of cartilage calcification at knee level in calcium pyrophosphate deposition disease. Arthritis Care Res (Hoboken). 2014;66(1):69–73.CrossRefGoogle Scholar
  8. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic non-pharmacologic and pharmacologic therapeutic approaches to hyperuricaemia. Arthritis Care Res. 2012a;64:1431.CrossRefGoogle Scholar
  9. Khanna D, FitzGerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012b;64:1447.CrossRefGoogle Scholar
  10. Loffler C, Sattler H, Peters L, Loffler U, Uppenkamp M, Bergner R. Distinguishing gouty arthritis from calcium pyrophosphate disease and other arthritides. J Rheumatol. 2015;42(3):513–20.CrossRefGoogle Scholar
  11. Neogi T, Jansen TA, Dalbeth N, et al. 2015 gout classification criteria. Arthritis Rheum. 2015;67(10):2557–68.CrossRefGoogle Scholar
  12. Rho YH, Zhu Y, Zhang Y, Reginato AM, Choi HK. Risk factors for pseudogout in the general population. Rheumatology (Oxford). 2012;51(11):2070–4.CrossRefGoogle Scholar
  13. Rosenthal AK. Basic calcium phosphate crystal-associated musculoskeletal syndromes: an update. Curr Opin Rheumatol. 2018;30(2):168–72.CrossRefGoogle Scholar
  14. Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374:2575–84.CrossRefGoogle Scholar
  15. Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, Leeb BF, Perez-Ruiz F, Pimentao J, Punzi L, Richette P, Sivera F, Uhling T, Watt I, Pascual E. European league against rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011a;70(4):563–70.CrossRefGoogle Scholar
  16. Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, Leeb BF, Perez-Ruiz F, Pimentao J, Punzi L, Richette P, Sivera F, Uhlig T, Watt I, Bardin T. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011b;70(4):571–5.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Eleftherios Pelechas
    • 1
  • Evripidis Kaltsonoudis
    • 1
  • Paraskevi V. Voulgari
    • 1
  • Alexandros A. Drosos
    • 1
  1. 1.Rheumatology Clinic - Department of Internal MedicineUniversity of IoanninaIoanninaGreece

Personalised recommendations